US 2009/0326031 A1 · ANTIVIRAL USE OF CATIONIC SURFACTANT

Abstract

Cationic surfactants derived from the condensation of fatty acids and esterified dibasic amino acids, such as from lauric acid and arginine, in particular the ethyl ester of the lauramide of the arginine monohydrochloride (LAE), may be used for the protection against the growth of the microorganisms. The cationic surfactants of this type are also effective against virus infections. Addition of LAE to cultures of Herpes virus type 1 Vaccinia virus and bovine parainfluenzae 3 virus leads to nearly complete reduction of the virus organisms in these cultures, such effects being observed after 5 and 60 minutes.

Claims12

Dependent claims

Use of a cationic surfactant derived from the condensation of fatty acids and esterified dibasic amino acids, according to the following formula (2):

where:
X− is Br−, Cl−, or HSO4−, a counter ion derived from an organic or inorganic acids, or an anion on the basis of a phenolic compound;
R1:
is a linear alkyl chain from a saturated fatty acid or hydroxyacid from 8 to 14 atoms of carbon bonded to the α-amino acid group through an amidic bond,
R2:
is a linear or branched alkyl chain from 1 to 18 carbon atoms or an aromatic group,
R3:
is
and n can be from 0 to 4,
for the treatment of virus infections.

7 more elements

Dependencies are inferred from the claim text.

Facts

Application

12/375,774Filed 3 Aug 2006

Priority

FR 060700531 Jul 2006

Published

31 Dec 2009

Term ends

Not estimatedThe source records don’t support an estimate.

Classification20 codes

A61K 31/155
Amines: amidines , e.g. guanidine , isourea , isothiourea
A23B 2/729
In the form of liquids or solids: organic compounds; Microorganisms; Enzymes
A23B 2/762
Organic compounds; Microorganisms; Enzymes: organic compounds containing nitrogen
A61K 31/223
Of acyclic acids, e.g. pravastatin: of alpha-aminoacids

Antiviral use of cationic surfactant

Life of this patent

Antiviral use of cationic surfactant

Life of this patent

Abstract

Claims12